Sumitomo Pharma stock
4506.TJPXSumitomo Pharma Co., Ltd., HealthcareISIN JP3495000006
57Score 57 out of 100, Neutral
Price and trend
68 / 100
Price history
−14% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 60).
The price is 36% below its 52-week high. Largest decline in 20 years: 93% (December 2018 to May 2024).
Chart figures for advanced users
- SMA 50$10.83
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.04
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)60
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.70
- The lowest closing price of the last twelve months.
- Resistance$19.94
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sumitomo Pharma Co., Ltd. belongs to the Drug Manufacturers (Specialty & Generic) industry (Japan) and, with a market value of $5.69B, is number 41 of 77 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $2.84B (up 13.7% year on year) and earnings of $669.17M (up 352.2%).
- MEQIRI Score 57 out of 100 (Neutral): rank 304 of 702 in Healthcare, median 53.
Show more
- The P/E is 19.6 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 13.4).
- Our model puts fair value at $12.24, with the price 1% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 146% of earnings over the last 12 months.Fundamentals 76
- Earnings per share growingUp 13.7% a year since 2021.
Weaknesses
- Volatile share priceVolatility 72% a year over the last 12 months.Stability 63
- Revenue shrinkingRevenue down 2.6% a year since 2021.Growth 13
Its standout strengths are momentum and fundamentals, while capital allocation and growth hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedClosing price of 12 Nov 2026, used by the daily score.
In our model the price counts as cheap below $8.16 and expensive above $24.48 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $3.43 (cash-flow model) and $21.06 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 6.1%. At 7.1% the fair value would be $12.14, at 5.1% it would be $12.37.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10.7% on the twelve months before. Revenue has changed sharply in recent years: $2.84B in 2026 after $1.97B in 2024.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 57%, operating 11%, net 24%. Last 12 months: net 9%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 29 Jan 2027in 77 days
- Last reported
- 30 Oct 2026EPS reported $0.30 (expected $0.18)above expectations
Analyst estimates
Earnings estimates have barely changed since 22 Oct 2026.
- Earnings per share
- $1.38+0.1%
- Revenue
- $3.55B0.0%
- Earnings per share
- $1.38−0.4%
- Revenue
- $3.87B0.0%
MEQIRI has stored the estimates since 22 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Sumitomo Pharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 57
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Lantheus HoldingsLNTH $6.62B76
- China Resources Sanjiu Medical & Pharmaceutical000999.SZ $6.25B73
- Apotex HealthAPTX.TO $6.17B68
- Gland PharmaGLAND.NS $5.8B70
- Ipca LaboratoriesIPCALAB.NS $5.12B69
- Laboratorios Farmaceuticos RoviROVI.MC $3.98B82
- Siegfried HoldingSFZN.SW $3.75B54
- Bausch Health CompaniesBHC $3.09B61
ETFs that hold Sumitomo Pharma
Held by 28 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI Japan Small Cap UCITS ETFIUS4 | 0.24% | 0.58% | €548.59M |
| Xtrackers Nikkei 225 UCITS ETF 2D EUR HedgedXDJE | 0.11% | 0.19% | €2.61B |
| iShares STOXX World Equity Multifactor UCITS ETFIBCZ | 0.06% | 0.30% | €826.24M |
Show 5 more
| L&G Japan Equity UCITS ETFETLR | 0.06% | 0.10% | €948.97M |
| Amundi Japan TOPIX II UCITS ETF EUR DistLYY4 | 0.05% | 0.45% | €633.4M |
| Amundi Prime Japan UCITS ETF DR (D)PR1J | 0.05% | 0.05% | €4.34B |
| iShares Core MSCI Japan IMI UCITS ETFEUNN | 0.05% | 0.12% | €7.17B |
| Vanguard FTSE Japan UCITS ETF EUR Hedged AccumulatingVJPE | 0.04% | 0.13% | €4.58B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.